

**$^{99m}\text{Tc}(\text{Sn})$ -Pyridoxylidenetryptophan:****A Potential Hepatobiliary Radiopharmaceutical of Rapid Hepatobiliary Transport and Low Urinary Excretion**

Makoto KATO-AZUMA

**I. Introduction**

Although the diagnosis of hepatobiliary disorders using  $^{99m}\text{Tc}(\text{Sn})$ -pyridoxylidenesoleucine [ $^{99m}\text{Tc}(\text{Sn})$ -PI] or  $^{99m}\text{Tc}$ -HIDA has been widely accepted in many clinical sites, there still exists a demand for new agents of rapid hepatobiliary transport and low urinary excretion. It has been reported that the urinary excretion of  $^{99m}\text{Tc}$ -(p-butyl) IDA is significantly small compared with other available agents; the slowness of its hepatobiliary transport, however, deters people from adopting this agent in routine diagnosis<sup>1)</sup>.

Our efforts have been focusing on the  $^{99m}\text{Tc}(\text{Sn})$ -pyridoxylidene-aminato system to find better hepatobiliary agents, and this rapid communication presents the results of preliminary studies on  $^{99m}\text{Tc}(\text{Sn})$ -pyridoxylidenetryptophan [ $^{99m}\text{Tc}(\text{Sn})$ -P.Trp], one of the promising agents of rapid hepatobiliary transport and low urinary excretion.

**II. Materials and methods<sup>2)</sup>****2.1 Preparation of Sn-pyridoxylidenetryptophan (Sn-P.Trp) reagent**

The preparation was analogous to that reported for Sn-pyridoxylidenesoleucine (Sn-PI)<sup>3,4)</sup>. Mixing a solution of pyridoxal hydrochloride-stannous chloride-ascorbic acid (70.0, 2.0 and 4.0  $\mu\text{mol}/\text{ml}$  each) with an equivalent volume of tryptophan-

sodium hydroxide solution (70.0 and 130.0  $\mu\text{mol}/\text{ml}$  each) gave a bright yellow reagent of Sn-P.Trp (pH 8.65).

**2.2 Preparation of  $^{99m}\text{Tc}(\text{Sn})$ -pyridoxylidenetryptophan [ $^{99m}\text{Tc}(\text{Sn})$ -P.Trp]**

$^{99m}\text{Tc}(\text{Sn})$ -P.Trp was prepared by mixing 1.5 ml of the freshly prepared Sn-P.Trp reagent with 1.5 ml of  $^{99m}\text{Tc}$ -pertechnetate saline solution (5–10 mCi, obtained by MEK extraction in our laboratory), and then warmed for two min in a boiling water bath<sup>5)</sup>. The viscosity of the solution increased moderately on cooling to room temperature, due to the formation of a fluidal gel; but this change caused no physical nor physiological trouble for the ordinary i.v. administration using a syringe with needle. No precipitation of crystalline substance was observed. Thus prepared  $^{99m}\text{Tc}(\text{Sn})$ -P.Trp was stable at room temperature for more than 48 hours.

**2.3 Preparation of  $^{99m}\text{Tc}(\text{Sn})$ -PI,  $^{99m}\text{Tc}$ -HIDA and  $^{99m}\text{Tc}$ -(p-butyl)-IDA**

The preparation of  $^{99m}\text{Tc}(\text{Sn})$ -PI has been described previously<sup>3–5)</sup>. The kit reagents of Sn-HIDA and Sn-(p-butyl) IDA were obtained commercially (CIS-Sorin), and the  $^{99m}\text{Tc}$ -labeling was performed according to the manufacturer's indications.

**2.4 Evaluation of labeling efficiency**

The labeling efficiency for each preparation was evaluated chromatographically using a silica gel plate developed with methanol: water: methylketone (9:1:10 v/v)<sup>4)</sup>.

**2.5 In vivo distribution study in rats**

The procedures were identical to that reported previously<sup>3,4)</sup>. Female Sprague-Dawley rats (8–9 weeks old, weighing 190–250 g) were used in this study.

\* Research & Development, Technical Section Nihon Medi-Physics Co., Ltd., 2-1, 4-chome, Takatsukasa, Takarazuka, Hyogo Pref. JAPAN 665.

受付: 55年3月26日 (1980年)

最終稿受付: 55年3月26日 (1980年)

別刷請求先: 兵庫県宝塚市高司4丁目2番1号 (☎665)

日本メジフィジックス株式会社

技術部 東

真 (旧姓 加藤)

Table 1 Organ distribution of  $^{99m}\text{Tc}-(\text{Sn})\text{-P. Trp}$  in rats\*

Organ	Time after i.v. administration					
	5 min	10 min	20 min	40 min	60 min	120 min
Liver	13.77 $\pm$ 2.87	5.51 $\pm$ 1.03	1.99 $\pm$ 0.39	1.26 $\pm$ 0.28	0.90 $\pm$ 0.09	0.69 $\pm$ 0.13
Small intestine	66.89 $\pm$ 5.26	79.98 $\pm$ 3.03	87.23 $\pm$ 2.27	90.64 $\pm$ 1.68	91.96 $\pm$ 1.37	93.26 $\pm$ 0.86
Large intestine	0.49 $\pm$ 0.13	0.15 $\pm$ 0.03	0.07 $\pm$ 0.02	0.03 $\pm$ 0.01	0.03 $\pm$ 0.00	0.02 $\pm$ 0.01
Stomach	0.11 $\pm$ 0.06	0.03 $\pm$ 0.01	0.02 $\pm$ 0.01	0.01 $\pm$ 0.01	0.00 $\pm$ 0.01	0.01 $\pm$ 0.00
Spleen	0.03 $\pm$ 0.00	0.02 $\pm$ 0.01	0.00 $\pm$ 0.00	0.01 $\pm$ 0.01	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00
Lung	0.46 $\pm$ 0.09	0.34 $\pm$ 0.06	0.18 $\pm$ 0.06	0.11 $\pm$ 0.03	0.06 $\pm$ 0.03	0.03 $\pm$ 0.01
Heart	0.07 $\pm$ 0.04	0.04 $\pm$ 0.02	0.02 $\pm$ 0.02	0.00 $\pm$ 0.00	0.01 $\pm$ 0.01	0.00 $\pm$ 0.00
Kidneys	0.97 $\pm$ 0.12	0.80 $\pm$ 0.10	0.62 $\pm$ 0.09	0.55 $\pm$ 0.11	0.52 $\pm$ 0.14	0.48 $\pm$ 0.12
1 ml/ Blood**	0.24 $\pm$ 0.04	0.15 $\pm$ 0.03	0.09 $\pm$ 0.02	0.05 $\pm$ 0.01	0.04 $\pm$ 0.00	0.03 $\pm$ 0.00
Carcass	13.26 $\pm$ 1.98	9.68 $\pm$ 0.83	6.37 $\pm$ 0.60	4.46 $\pm$ 0.27	3.68 $\pm$ 0.24	2.86 $\pm$ 0.17
Urine	0.71 $\pm$ 0.21	1.20 $\pm$ 0.14	1.52 $\pm$ 0.16	1.76 $\pm$ 0.11	1.92 $\pm$ 0.15	2.13 $\pm$ 0.14

\* Mean results for four rats  $\pm$  1 s.d. Data are expressed as % of total administered dose.

\*\* Normalized to the body weight of 200 g.




Fig. 1 Blood clearance of radioactivity after i.v. administration of  $^{99m}\text{Tc}$ -labeled hepatobiliary agents in rats. Each point represents mean result for four animals.  $^{99m}\text{Tc}-(\text{Sn})\text{-P.Trp}$ ,  $^{99m}\text{Tc}-(\text{Sn})\text{-PI}$  and  $^{99m}\text{Tc}\text{-HIDA}$  showed almost similar clearance, while  $^{99m}\text{Tc}-(\text{p-butyl})\text{IDA}$  showed a relatively delayed blood clearance.

### III. Results and discussion

The chromatographic analysis revealed that the labeling efficiency for each preparation was






Fig. 2 Radioactivity in liver at various time intervals after i.v. administration of  $^{99m}\text{Tc}$ -labeled hepatobiliary agents in rats. Each point represents mean results for four animals.  $^{99m}\text{Tc}-(\text{Sn})\text{-P. Trp}$  showed a significantly fast disappearance from liver compared with other three agents.

practically 100%; neither unreacted pertechnetate ( $R_f$  0.98–1.00) nor reduced-hydrolyzed technetium (at the origin) was detected in any preparation. The in vivo distribution of each  $^{99m}\text{Tc}$ -labeled agent (Table 1, Fig. 1–4) also indicated the absence of pertechnetate and hydrolyzed



**Fig. 3** Radioactivity in small intestine at various time intervals after i.v. administration of  $^{99m}\text{Tc}$ -labeled hepatobiliary agents in rats. Each point represents mean result for four animals.  $^{99m}\text{Tc}(\text{Sn})\text{-P.Trp}$  showed a significantly rapid biliary excretion into small intestine compared with other three agents.



**Fig. 4** Cumulative urinary excretion of radioactivity after i.v. administration of  $^{99m}\text{Tc}$ -labeled hepatobiliary agents in rats. Each point represents mean result for four animals. The urinary excretion of  $^{99m}\text{Tc}(\text{Sn})\text{-P.Trp}$  was slightly lower than that of  $^{99m}\text{Tc}(\text{p-butyl})\text{IDA}$ .

technetium in the preparation.

Table 1 shows the distribution of  $^{99m}\text{Tc}(\text{Sn})\text{-P.Trp}$  in rats at various time intervals after i.v. administration, and Fig. 1–Fig. 4 illustrate the results of the comparative distribution studies on  $^{99m}\text{Tc}(\text{Sn})\text{-P.Trp}$ ,  $^{99m}\text{Tc}(\text{Sn})\text{-PI}$ ,  $^{99m}\text{Tc}\text{-HIDA}$  and  $^{99m}\text{Tc}(\text{p-butyl})\text{-IDA}$ . The blood clearance of  $^{99m}\text{Tc}(\text{Sn})\text{-P.Trp}$  was almost identical to those of  $^{99m}\text{Tc}(\text{Sn})\text{-PI}$  and  $^{99m}\text{Tc}\text{-HIDA}$ , and significantly faster than that of  $^{99m}\text{Tc}(\text{p-butyl})\text{IDA}$  (Fig. 1). The biliary excretion patterns of these agents can be seen in Fig. 2 and Fig. 3. The excretion of  $^{99m}\text{Tc}(\text{Sn})\text{-P.Trp}$  into the bile was significantly faster than those of other three agents, and  $^{99m}\text{Tc}(\text{p-butyl})\text{IDA}$  showed the mostly delayed excretion. Wistow et al. also reported a relatively slow biliary excretion of  $^{99m}\text{Tc}(\text{p-butyl})\text{IDA}$  in baboons and humans<sup>1)</sup>. The urinary excretion rate of  $^{99m}\text{Tc}(\text{Sn})\text{-P.Trp}$  was extremely small (Table 1, Fig. 4), whose 2%/two-hour excretion rate is comparable to that of  $^{131}\text{I}$ - or  $^{123}\text{I}$ -labeled rose bengal<sup>1)</sup>.

Wistow and his co-workers reported that the increase of the molecular lipophilicity of N-substituted iminodiacetic acid (IDA) derivatives retards the biliary excretion of their  $^{99m}\text{Tc}$  complexes, nevertheless the high-lipophilicity is effective in decreasing the urinary excretion<sup>1,6)</sup>. Therefore, in the system of  $^{99m}\text{Tc}$ -labeled IDA derivatives, the fast hepatobiliary transport seems to be incompatible with the low urinary excretion. On the other hand, the author reports in this communication that  $^{99m}\text{Tc}(\text{Sn})\text{-P.Trp}$  undergoes surprisingly rapid biliary excretion which is compatible with its extremely low urinary excretion. It seems that there may exist some differences in the mechanisms of the hepatobiliary transport between  $^{99m}\text{Tc}(\text{Sn})\text{-P.Trp}$  and  $^{99m}\text{Tc}$ -labeled IDA derivatives, but further precise studies should be done in this respect.

Further works are now in progress including scintigraphic studies using higher animal species, in vivo distribution studies in animals with artificial hepatobiliary disorders. All the results obtained to date strongly suggest the usefulness of  $^{99m}\text{Tc}(\text{Sn})\text{-P.Trp}$  as an improved hepatobiliary radio-pharmaceutical. Details of the investigation will be reported soon.

### Acknowledgments

The author expresses his appreciation to Dr. M. Hazue for his useful advice and discussion.

### References

- 1) Wistow BW, Subramanian G, Gagne GM, et al: Experimental and clinical trials of new  $^{99m}\text{Tc}$ -labeled hepatobiliary agents. *Radiology* **128**: 793–794, 1978
- 2) The details of the chemistry and preparation of the complexes will be published elsewhere. The patent applications covering various analogous compounds and method of the similar nuclear-medical characteristics are now pending.
- 3) Kato M and Hazue M:  $^{99m}\text{Tc}$ -(Sn)-pyridoxylidenevaline and  $^{99m}\text{Tc}$ -(Sn)-pyridoxylideneisoleucine: potential radiopharmaceuticals for hepatobiliary tract imaging. *Jap J Nucl Med* **14**: 927–931, 1977
- 4) Kato M and Hazue M: Tc- $^{99m}\text{Sn}$  Pyridoxylideneamines: preparation and biologic evaluation. *J Nucl Med* **19**: 397–406, 1978
- 5) Kato M: In vivo distribution of Tc- $^{99m}\text{Sn}$ -pyridoxylideneisoleucine: effects of storage and labeling conditions. concise communication. *J Nucl Med* **20**: 1189–1193, 1979
- 6) Wistow BW, Subramanian G, Van Heertum RL, et al: An evaluation of  $^{99m}\text{Tc}$ -labeled hepatobiliary agents. *J Nucl Med* **18**: 455–461, 1977

## 要 旨

$^{99m}\text{Tc}$ -(Sn)-ピリドキシレントリプトファン：尿中排泄が少なく、肝胆道移行が迅速な肝胆道系イメージング用放射性医薬品としての可能性

東 真

日本メジフィジックス株式会社 技術部

スズ還元法によって  $^{99m}\text{Tc}$ -(Sn)-ピリドキシレントリプトファン [ $^{99m}\text{Tc}$ -(Sn)-P. Trp] を調製し、ラットにおける体内動態を現在臨床に供されている3種のテクネチウム製剤 [ $^{99m}\text{Tc}$ -(Sn)-PI,  $^{99m}\text{Tc}$ -HIDA,  $^{99m}\text{Tc}$ -(p-butyl)IDA] と比較、検討した。

静脈内投与後の血中消失率は、 $^{99m}\text{Tc}$ -(Sn)-PI にほぼ等しく、 $^{99m}\text{Tc}$ -(p-butyl) IDA に比して有意にや速かであった。肝臓から小腸への移行は極めてや速かであり、 $^{99m}\text{Tc}$ -(Sn)-PI および  $^{99m}\text{Tc}$ -HIDA と比較しても有意に迅速な肝胆道移行を示した。

また、 $^{99m}\text{Tc}$ -(Sn)-P. Trp の静脈内投与後1時間における尿中への排泄量は投与総放射能の1.9%と少なく、 $^{99m}\text{Tc}$ -(p-butyl) IDA の尿中排泄をも下

回った。

これらの結果は、 $^{99m}\text{Tc}$ -(Sn)-P. Trp が (1) 迅速な血中からの消失、(2) 迅速な肝胆道移行、(3) 極めて少ない尿中排泄、という3つの優れた特性を備えた新しい肝胆道系イメージング剤となり得ることを示唆した。

ウキギを用いたイメージング実験、肝障害を生じせしめた動物を用いた検討などを続行中であり、この製剤の有用性を示唆する結果が得られつつある。近々詳細を発表する予定である。

**Key words:**  $^{99m}\text{Tc}$ -(Sn)-pyridoxylidenetriptyphan, hepatobiliary imaging agent